The full guideline for the management of non-tuberculous mycobacterial pulmonary disease is published in Thorax.
IntroductIon
The full guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) is published in Thorax. 1 The key features of the guideline are highlighted in a short article published to accompany the full guideline. 2 The following is a summary of the recommendations and good practice points. The sections referred to in the summary refer to the full guideline.
bAckground Since the publication of the British Thoracic Society (BTS) Guideline on the 'Management of opportunistic mycobacterial infections' 3 in 2000, our understanding of the epidemiology, microbiology and management of NTM-PD has advanced. The incidence and prevalence of NTM-PD is increasing and is most likely explained by improved clinician awareness and enhanced detection methods, as well as a variety of changing environmental, mycobacterial and host factors. Technological advances in molecular microbiology have revolutionised our understanding of NTM taxonomy and it is now appreciated that species and subspecies often differ in their pathogenicity and treatment response. While there remains a dearth of contemporary randomised controlled trial data to inform practice, the Guideline Development Group have sought to combine the best available evidence with clinical experience to create a pragmatic management guideline.
target audience for the guideline This guideline is aimed at healthcare practitioners who are involved in the care of individuals with NTM-PD, which will include hospital specialists in respiratory medicine, infectious diseases, paediatrics, microbiology, immunology and radiology.
Groups covered within the guideline include: (a) individuals without pre-existing lung disease (de novo NTM infection); (b) individuals with chronic obstructive pulmonary disease and other chronic inflammatory lung diseases; (c) individuals with bronchiectasis; (d) individuals with cystic fibrosis; (e) individuals with a primary or secondary immunodeficiency; (f) individuals being considered for and following lung transplantation. Groups not covered within the guideline are patients with extrapulmonary NTM disease, neonates (birth to 28 days), infants (1-12 months), and patients with HIV infection.
scope of the guideline 1. Epidemiology-incidence, prevalence and risk factors 2. Microbiology-types of samples, detection and speciation 3. Definition of NTM-PD and indications for treatment 4. Antibiotic treatment regimens for specific NTM species 5. Role of drug susceptibility testing 6. Non-antibiotic treatment-interferon-gamma, Mycobacterium vaccae Open Access 7. Investigation of individuals suspected of having NTM-PD and investigations to be undertaken during and after treatment 8. Role of thoracic surgery 9. Impact of NTM on lung transplant eligibility Methodology This guideline is based on the best available evidence. The methodology used to write the guideline adheres strictly to the criteria as set by the AGREE (Appraisal of Guidelines for Research and Evaluation) collaboration, which is available online www. agreetrust. org/ resource-centre/ agree-ii/. The BTS Standards of Care Committee guideline production manual is available at http://www. brit-thoracic. org. uk/ guidelines-and-quality-standards/.
clinical questions, literature search and appraisal of the literature Clinical questions were structured in the Population, Intervention, Comparison, Outcome format (see online appendix 1 in the full guideline), to define the scope of the guideline and inform the literature search.
The searches were first run in November 2012 and updated in June 2015 (see full guideline online appendix 1).
Appraisal was performed to be compliant with the AGREE collaboration. Please see the full guideline for further details.
considered judgement and grading of evidence The Guideline Development Group used the evidence tables (see full guideline online appendix 2) to judge the body of evidence and grade recommendations for this guideline (tables 1 and 2). Where evidence was lacking to answer the formulated clinical questions, expert opinions were obtained through consensus. The following were considered in grading of the recommendations: ► The available volume of the body of evidence. Extrapolated evidence from studies rated as 2+ ✔ Important practical points for which there is no research evidence, nor is there likely to be any research evidence. The guideline committee wishes to emphasise these as good practice points.
RCT, randomised controlledtrial.
Open Access ► How applicable the obtained evidence was in making recommendations for the defined target audience of this guideline. ► Whether the evidence was generalisable to the target population for the guideline. ► Whether there was a clear consistency in the evidence obtained to support recommendations. ► What the implications of recommendations would be on clinical practice in terms of resources and skilled expertise. ► Cost-effectiveness was not reviewed in detail as indepth economic analysis of recommendations falls beyond the scope of this guideline. Recommendations were graded from A to D as indicated by the strength of the evidence as shown in table 2. In line with the Scottish Intercollegiate Guideline Network (SIGN) guidance, 'minus' evidence was considered in context but in the absence of other 'plus' supporting evidence, it was discussed among the Guideline Development Group regarding that point and any recommendation hence made was grade D. Important practical points lacking any research evidence, nor likely to be research evidence in the future were highlighted as 'good practice points'.
drafting the guideline The Guideline Development Group corresponded regularly by email and meetings of the full group were held in May and July 2012, July and September 2013, January, April and November 2014 and June 2015 as well as a number of teleconferences. The Guideline Development Group were asked if they agreed or disagreed with the draft recommendations and good practice points in an anonymous electronic survey administered by the BTS project co-ordinator in Spring 2016. The Guideline Development Group had agreed at the start of the guideline development process that 80% or more agreement would be the threshold for acceptance. Although not always unanimous, 80% or greater agreement was achieved for all recommendations and good practice points in the first round of voting.
The BTS Standards of Care Committee (SOCC) reviewed the draft guideline in November 2016. The draft guideline was made available online in February 2017 for public consultation and circulated to all the relevant stakeholders. The BTS SOCC rereviewed the revised draft guideline in June 2017 and final SOCC approval for publication was granted in July 2017.
This BTS Guideline will be reviewed within 5 years from publication date. Good practice point ✔ If there is high clinical suspicion of NTM infection but negative sample cultures, consider discussing with a mycobacterial reference laboratory about (i) the possibility of culture on alternative media, at different temperatures, and/or for extended durations or (ii) the utility of molecular detection methods.
section 8: What microbiological tests should be used to speciate and type ntM from respiratory samples? Recommendations ► All NTM isolates from respiratory samples should be identified to at least species level using validated molecular or mass spectrometry techniques (grade B). ► Isolates of M. abscessus should be subspeciated using appropriate molecular techniques (grade C).
► If person-to-person transmission of M. abscessus is suspected, isolates should be typed, preferably using whole genome sequencing (grade C). Good practice points ✔ Susceptibility testing should only be carried out on isolates where there is clinical suspicion of disease (to avoid unnecessary cost and conserve laboratory resources). ✔ Reporting of minimum inhibitory concentration (MIC) and critical concentration rather than susceptible or resistant may be more appropriate in the belief that a drug that has a very high MIC is unlikely to be active in vivo, whereas one just above a putative 'critical concentration' may have some activity, especially if combined with additive or synergistic agents.
section 10: What investigations should be performed in patients suspected of having ntM-pd? (see figure 1)
Respiratory tract cultures
Recommendations ► A minimum of two sputum samples collected on separate days should be sent for mycobacterial culture when investigating an individual suspected of having NTM-PD (grade D) (see figure 1 ).
Open Access Good practice point ✔ The views of the affected individual should be sought on the potential risks and benefits of starting NTM treatment versus observation (ie, longitudinal assessment of symptoms, radiological change and mycobacterial culture results). Good practice points ✔ Individuals with clarithromycin-resistant MAC-PD should be managed in collaboration with a physician experienced in managing NTM-PD. ✔ Individuals with a history of treatment intolerance or treatment failure should be managed in collaboration with a physician experienced in managing NTM-PD.
Open Access Continuation phase: nebulised amikacin † and oral clarithromycin 500 mg twice daily or azithromycin 250-500 mg daily and 1-3 of the following antibiotics guided by drug susceptibility results and patient tolerance: oral clofazimine 50-100 mg daily ‡ oral linezolid 600 mg daily or twice daily oral minocycline 100 mg twice daily oral moxifloxacin 400 mg daily oral cotrimoxazole 960 mg twice daily Constitutive macrolideresistant isolates Initial phase: ≥1 month* intravenous amikacin 15 mg/kg daily or 3×per week † and intravenous tigecycline 50 mg twice daily and where tolerated intravenous imipenem 1 g twice daily Continuation phase: nebulised amikacin † and 2-4 of the following antibiotics guided by drug susceptibility results and patient tolerance: oral clofazimine 50-100 mg daily ‡ oral linezolid 600 mg daily or twice daily oral minocycline 100 mg twice daily oral moxifloxacin 400 mg daily oral cotrimoxazole 960 mg twice daily *Due to the poorer response rates in patients with inducible or constitutive macrolide-resistant isolates and the greater efficacy of antibiotics administered through the intravenous route, -extending the duration of intravenous antibiotic therapy to 3-6 months in those that can tolerate it may be the most appropriate treatment strategy in this subgroup of patients.
†Substitute intravenous/nebulised amikacin with an alternative antibiotic if the M. abscessus is resistant to amikacin (ie, MIC >64 mg/L or known to have a 16S rRNA gene mutation conferring constitutive amikacin resistance). ‡Start clofazimine during the initial phase of treatment if tolerated as steady state serum concentrations may not be reached until ≥30 days of treatment.
setron (note potential for QT interval prolongation) and/or aprepitant should be prescribed to individuals receiving tigecycline and/or imipenem (grade D).
► Nebulised amikacin may be considered in place of intravenous amikacin when intravenous administration is impractical, contraindicated or long-term treat-Open Access Good practice points ✔ Individuals with NTM-PD in whom lung resection surgery is being considered should have a comprehensive assessment of cardiopulmonary status in line with current guidance for lung cancer resection. ✔ Nutritional status should be optimised prior to lung resection surgery. good practice points ✔ Individuals with NTM-PD should demonstrate an ability to tolerate optimal antibiotic therapy before listing for lung transplantation. ✔ Progressive NTM-PD despite optimal antibiotic therapy is likely to be a contraindication to listing for lung transplantation.
section 18: ntM drug monograph The treatment of NTM-PD involves complex drug regimens that are commonly associated with intolerance and toxicity. The purpose of this monograph is to facilitate antibiotic prescribing in people with NTM-PD, but it should only be used in conjunction with, and not as a substitute for, local/national prescribing formularies. The monograph also provides guidance on the type and frequency of monitoring for drug toxicity which must, however, be determined on a case-by-case basis, informed by patient symptoms at each clinical encounter, and adjusted according to existing comorbidities. The information in this section of the guideline is provided as an aid to monitoring adverse effects and is correct at the time of publication. Readers are advised to confirm the latest information with their pharmacy colleagues. The NTM drug monograph can be found as section 18 of the full guideline and also on the BTS website at: www. brit-thoracic. org. uk/.
onlIne AppendIces Available at: https://www. brit-thoracic. org. uk/ standardsof-care/ guidelines/ bts-guidelines-for-non-tuberculousmycobacteria/
